Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: potential of platelet’s signaling cascades as new outcome measures in clinical trialsDavid Pellerin, François Corbin, Mathieu Fradet et al.|Biomarkers|2016Cited by 50